Press Releases
Partnership for Safe Medicines’ Statement on Congressional Action to Permanently Schedule Fentanyl-Related Analogues and Substances
Shabbir Safdar, Executive Director of the Partnership for Safe Medicines, released the following statement today in response to Congressional actions to permanently scheduling illicitly manufactured and deadly fentanyl…
[...]What is “Permanently Scheduling” Fentanyl-related Substances and Analogues, and Why is it so Important?
Learn why permanently scheduling fentanyl-related substances and analogues on Schedule I of the Controlled Substances Act is an important policy tool in the fight against fentanyl-laced counterfeit medicines.
[...]PSM Applauds Senate Passage of the Safeguarding Therapeutics Act
The Partnership for Safe Medicines (PSM) applauds the passage of H.R. 5663 – the Safeguarding Therapeutics Act. The bipartisan bill, introduced by Congressman Brett Guthrie (KY-02-R) and Congressman Eliot Engel (NY-16-D), was passed via unanimous consent in the Senate on December 8th.
[...]Statement on Litigation Challenging Legality of Administration’s Final Rule Permitting State-Sponsored Drug Importation From Canada
Today, PhRMA, The Partnership for Safe Medicines and Council for Affordable Health Coverage initiated litigation in the U.S. District Court for the District of Columbia challenging action by HHS and FDA permitting pharmacists and wholesalers, pursuant to state-sponsored programs, to import certain prescription drugs from Canada into the United States without drug manufacturers’ authorization or oversight.
[...]Deadly Counterfeit Pills Found in All 50 U.S. States; Deaths Now Reported in 42 of Them.
With the recent report that police in Maui, Hawaii seized 400 counterfeit oxycodone pills made with fentanyl on October 2, 2020, the United States has reached a sobering milestone: public sources have reported about fake pills made with fentanyl in all 50 states.
[...]Statement on Trump Administration Executive Order on Drug Importation
Washington, D.C. (July 24, 2020) – Shabbir Safdar, executive director of the Partnership for Safe Medicines, released the following statement in response to President Trump’s executive order signed today on the importation of prescription drugs:
[...]PSM Statement on the New Pilot Program from NTIA and FDA
The Partnership for Safe Medicines (PSM) applauds the Food and Drug Administration (FDA) and the National Telecommunications and Information Administration (NTIA) pilot program established this week to curb unapproved opioids illegally available online by potentially suspending or blocking offending domain names.
[...]Policy Resolution on Counterfeit Device Destruction, May 8, 2020
The following policy resolution was passed unanimously at the May 8, 2020 Advisory Board meeting: The Partnership for Safe Medicines believes that counterfeit medical devices are dangerous to American patients and that the U.S. Food and Drug Administration (FDA) should have the unequivocal power to seize and destroy these dangerous products whether they are found…
[...]Policy Resolution, January 8, 2020
The following policy resolution was passed unanimously at the Jan. 8, 2020 board meeting in Washington DC. The governing board of the Partnership for Safe Medicines votes today to reiterate that the Partnership is organized to focus entirely of the safety of medicine as it travels through the supply chain, as we have since our…
[...]PSM Statement on the passage of S.3201, which extends the DEA’s temporary scheduling of fentanyl-related substances as Schedule I for 15 months.
The Partnership for Safe Medicines (PSM) stands with our law enforcement partners in commending the U.S. Senate and the U.S. House of Representatives for their swift passage of S.3201, which would extend the DEA’s temporary scheduling of fentanyl-related substances to be Schedule I controlled substances for an additional 15 months. Without this reauthorization, criminals could…
[...]